Novartis AG stock gains 2% on SIX Swiss Exchange amid strong SMI performance and positive pharma sector momentum

The Novartis AG stock (ISIN: CH0012005267) rose up to 2.14% on the SIX Swiss Exchange on March 25, 2026, outperforming the SMI index. This intraday surge highlights resilience in the pharmaceutical sector for US investors tracking global healthcare leaders. Key details on price action, context, and implications ahead.

The Novartis AG stock delivered a strong performance on the SIX Swiss Exchange, climbing as much as 2.14% to 119.62 CHF during trading on March 25, 2026. This gain positioned it among the top performers in the Swiss Market Index (SMI), which itself advanced 1.62% to 12,024.96 points by late session. The move reflects broader positive sentiment in European pharma stocks, with Novartis standing out due to its robust pipeline and operational stability.

As of: 26.03.2026

Dr. Elena Vasquez, Senior Pharma Equity Analyst: Novartis AG exemplifies the defensive strength of big pharma in uncertain markets, with its recent price action underscoring pipeline durability for long-term US portfolios.

Recent Price Action on SIX Swiss Exchange

Novartis AG stock opened at 118.24 CHF on the SIX Swiss Exchange on March 25, 2026, and quickly gained traction. By midday, it was up 1.2% at 118.92 CHF, with trading volume reaching 545,804 shares. The stock pushed higher in the afternoon, hitting an intraday high of 119.90 CHF before settling at 119.62 CHF, a 2.14% increase from the open.

This performance contributed momentum to the SMI, which closed stronger at 12,024.96 points. Volume in Novartis shares exceeded 931,313 by late afternoon, indicating solid investor interest. Compared to its 52-week range, the stock remains 10.16% below its February 27, 2026, high of 131.00 CHF but 31.80% above the April 10, 2025, low of 81.10 CHF.

The Novartis AG stock was last seen on SIX Swiss Exchange at around 119.62 CHF. Such intraday gains in a leading pharma name often signal confidence in upcoming catalysts, particularly as markets digest recent earnings and pipeline updates.

Pharma Sector Context Driving the Gain

Novartis operates as a global healthcare leader, focusing on innovative medicines across oncology, immunology, neuroscience, and cardiovascular areas. The recent stock strength aligns with positive sector tailwinds, including fresh study results in dermatology and steady analyst coverage. Deutsche Bank recently reiterated a Buy rating, while UBS maintains Neutral, reflecting mixed but generally supportive views.

In the broader pharma landscape, companies like Novartis benefit from resilient demand for chronic treatments amid economic uncertainty. The firm's Q4 2025 results showed earnings per share of 1.01 CHF, down from 1.25 CHF year-over-year, with revenue at 10.66 billion CHF, a 7.64% decline. However, investors appear focused on forward guidance, with Q1 2026 results due April 28, 2026.

Analysts project full-year 2026 EPS at 8.81 USD, highlighting potential recovery. This positions Novartis AG stock favorably against peers, especially as US investors seek diversified exposure to Swiss pharma giants with strong US market presence.

Why US Investors Should Watch Novartis AG Stock Now

For US investors, Novartis AG offers a compelling blend of global diversification and US-centric revenue streams. A significant portion of its sales comes from the US market, where flagship drugs like Entresto and Cosentyx drive growth in cardiology and immunology. The stock's ADR listing provides easy access via US exchanges, making it a straightforward addition to portfolios seeking healthcare stability.

Amid volatility in US tech and cyclicals, European pharma like Novartis provides a defensive anchor. Recent gains on SIX Swiss Exchange underscore this appeal, as the stock outperforms amid SMI strength. With projected 2026 EPS of 8.81 USD, it trades at a valuation attractive for yield-focused investors.

US portfolio managers value Novartis for its patent-protected pipeline and M&A discipline post-spin-offs. The company's focus on high-growth areas positions it well against US peers like Eli Lilly or Merck, offering lower volatility with comparable upside.

Pipeline and Strategic Initiatives Fueling Momentum

Novartis continues to advance its pipeline, with recent dermatology study results boosting sentiment. Key programs in radioligand therapies and gene therapies target oncology, where unmet needs persist. These developments differentiate Novartis from pure-play biotech, providing scale and R&D firepower.

Strategically, the company has streamlined operations, divesting non-core assets to focus on innovative medicines. This has improved margins and free cash flow, supporting dividends and buybacks. Investors on SIX Swiss Exchange reacted positively to this execution, as evidenced by the volume surge.

Upcoming milestones include Q1 earnings on April 28, 2026, where updates on peak sales for new launches could catalyze further gains. For US investors, this translates to potential alpha in a sector rotation toward healthcare.

Risks and Open Questions for Novartis AG Stock

Despite the upside, challenges remain. Patent expirations loom for blockbusters, pressuring revenue if pipeline successors underperform. Regulatory hurdles, particularly in the US FDA, could delay approvals and impact timelines.

Macro risks include currency fluctuations, with CHF strength affecting reported USD earnings. Competition intensifies in immunology and oncology, where biosimilars erode pricing power. Recent Q4 revenue dip highlights volume pressures in select markets.

Analyst divergence—Buy from Deutsche Bank versus Neutral from UBS—signals uncertainty. The stock's position 10% off 52-week highs suggests room for upside but also vulnerability to sector selloffs. US investors must weigh these against the defensive profile.

Valuation and Long-Term Outlook

At 119.62 CHF on SIX Swiss Exchange, Novartis AG stock reflects a balanced valuation. Forward EPS estimates support a case for mid-teens upside if execution continues. Dividend yield remains competitive, appealing to income investors.

Long-term, growth in emerging markets and US biologics expansion underpin optimism. Compared to SMI peers, Novartis shows relative strength, with 29.56% one-year gains in some tracking lists. US investors can leverage this through ADRs for seamless integration.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.